Pacific Biosciences Of California (PACB) Capital Expenditures (2010 - 2026)

Pacific Biosciences Of California has reported Capital Expenditures for 17 years, with the latest figure at $1.6 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 182.73% year-over-year to $1.6 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 94.04% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, down 56.14% from the prior year.
• Capital Expenditures was $1.6 million for Q2 2026 at Pacific Biosciences Of California, down from $3.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $4.9 million in Q4 2022, with the low at -$787000.0 in Q3 2024.
• Average Capital Expenditures over 5 years is $2.2 million, with a median of $1.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 807.23% in 2022, then slumped 194.82% in 2024.
• Over 5 years, Capital Expenditures stood at $4.9 million in 2022, then sank by 58.73% to $2.0 million in 2023, then slipped by 20.11% to $1.6 million in 2024, then sank by 46.75% to $861000.0 in 2025, then surged by 80.6% to $1.6 million in 2026.
• The last three Capital Expenditures figures came in at $1.6 million (Q2 2026), $3.0 million (Q1 2026), and $861000.0 (Q4 2025), per Business Quant data.